Results 31 to 40 of about 12,608 (240)

Evaluating Treatment Mechanisms of Varenicline: Mediation by Affect and Craving.

Nicotine & Tobacco Research, 2022
INTRODUCTION Negative reinforcement models posit that relapse to cigarette smoking is driven in part by changes in affect and craving during the quit attempt.
S. Tonkin, C. Colder, M. Mahoney, G. Swan, P. Cinciripini, R. Schnoll, T. George, R. Tyndale, Larry W Hawk   +8 more
semanticscholar   +1 more source

Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2021
Importance Smoking cessation medications are routinely used in health care. Research suggests that combining varenicline with the nicotine patch, extending the duration of varenicline treatment, or both, may increase cessation effectiveness.
T. Baker, Megan E. Piper, Stevens S. Smith, D. Bolt, J. Stein, M. Fiore   +5 more
semanticscholar   +1 more source

ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease

Cornea, 2021
Supplemental Digital Content is Available in the Text. Purpose: The purpose of this trial was to evaluate the safety and efficacy of OC-01 (varenicline solution), a nicotinic acetylcholine receptor agonist nasal spray, on signs and symptoms of dry eye ...
David L Wirta, G. Torkildsen, Blair Boehmer, D. Hollander, Edward Bendert, Lijuan Zeng, Michael Ackermann, J. Nau   +7 more
semanticscholar   +1 more source

Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial.

American Journal of Psychiatry, 2021
OBJECTIVE Pharmacological treatments that can concomitantly address cigarette smoking and heavy drinking stand to improve health care delivery for these highly prevalent co-occurring conditions.
L. Ray, ReJoyce Green, Craig K. Enders, A. Leventhal, E. Grodin, Gang Li, Aaron C. Lim, E. Hartwell, A. Venegas, Lindsay R Meredith, Steven J. Nieto, S. Shoptaw, Diana Ho, K. Miotto   +13 more
semanticscholar   +1 more source

A case report on varenicline induced delirium in an alcohol and nicotine dependent patient

Indian Journal of Psychological Medicine, 2015
Varenicline is a smoking cessation agent. Varenicline acts as a partial agonist of α4β2 neuronal nicotinic acetylcholine receptor and prevents nicotine binding to the same.
A Lakshmi Narayan, H S Virupaksha, G Thejaswi, G R Saraswathy, V Madhavan, Murali Thyloth   +5 more
doaj   +1 more source

Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. [PDF]

PLoS ONE, 2016
UNLABELLED:Schizophrenic patients have a high rate of smoking and cognitive deficits which may be related to a decreased number or responsiveness of nicotinic receptors in their brains.
Robert C Smith, Revital Amiaz, Tian-Mei Si, Lawrence Maayan, Hua Jin, Sylvia Boules, Henry Sershen, Chunbo Li, Juanjuan Ren, Yanhong Liu, Mary Youseff, Abel Lajtha, Alessandro Guidotti, Mark Weiser, John M Davis   +14 more
doaj   +1 more source

Varenicline: For smoking cessation

Kathmandu University Medical Journal, 1970
Varenicline, a partial agonist of α4β2 nicotinic acetylcholine receptor (nAChR), is the most recently approved drug for smoking cessation. Despite the availability of effective treatments for smoking cessation, such as nicotine replacement therapy and Bupropion sustained-release, abstinence rates remain less than optimal.
Pinakini K. Shankar, J. Rao
openaire   +4 more sources

Varenicline and Risk of Self-Harm: A Nested Case-Control Study. [PDF]

PLoS ONE, 2016
BACKGROUND:Smoking remains a serious public health concern. Pharmacotherapy for smoking cessation, including bupropion and varenicline, are proven means to increase quit rates.
Mina Tadrous, Diana Martins, Zhan Yao, Muhammad M Mamdani, David N Juurlink, Tara Gomes, Tony Antoniou   +6 more
doaj   +1 more source

Alcohol use disorder severity moderates clinical response to varenicline.

Alcoholism: Clinical and Experimental Research, 2021
BACKGROUND In a multisite clinical trial, varenicline was effective in reducing drinking in both smoking- and nonsmoking patients with alcohol dependence.
S. Donato, ReJoyce Green, L. Ray
semanticscholar   +1 more source

Use of varenicline and nicotine replacement therapy in people with and without general practitioner-recorded dementia: retrospective cohort study of routine electronic medical records

BMJ Open, 2019
Objectives Our primary objective was to estimate smoking prevalence and prescribing rates of varenicline and nicotine replacement therapy (NRT) in people with and without general practitioner (GP)-recorded dementia.
Amy Taylor, Tim Jones, Taha Itani, Richard Martin, Gemma Taylor, Kyla Thomas, Neil Davies   +6 more
doaj   +1 more source